Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/12684
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTebbutt, Niall Cen
dc.contributor.authorKotasek, Dusanen
dc.contributor.authorBurris, Howard Aen
dc.contributor.authorSchwartzberg, Lee Sen
dc.contributor.authorHurwitz, Herberten
dc.contributor.authorStephenson, Joeen
dc.contributor.authorWarner, Douglas Jen
dc.contributor.authorChen, Lisaen
dc.contributor.authorHsu, Cheng-Pangen
dc.contributor.authorGoldstein, David Ben
dc.date.accessioned2015-05-16T02:24:45Z
dc.date.available2015-05-16T02:24:45Z
dc.date.issued2015-03-15en
dc.identifier.citationCancer Chemotherapy and Pharmacology 2015; 75(5): 993-1004en
dc.identifier.govdoc25772756en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/12684en
dc.description.abstractThis study assessed the safety, efficacy, and pharmacokinetics of motesanib, a multitargeted small molecule angiogenesis inhibitor, with and without panitumumab, in combination with FOLFIRI or FOLFOX in patients with metastatic colorectal cancer (mCRC).This open-label, phase 1b, two-part, multicenter study in patients with mCRC and ≤1 prior treatment evaluated escalating doses (50, 75, 100, or 125 mg QD, 75 mg BID) of motesanib with panitumumab and chemotherapy (Part 1) and the target dose of motesanib with chemotherapy (Part 2).At 17 sites in the USA and Australia, 119 patients were enrolled between December 2004 and February 2010. In Part 1 [motesanib plus panitumumab/FOLFIRI (n = 36) or plus panitumumab/FOLFOX (n = 17)], all motesanib doses tested were tolerated and 125 mg QD was deemed the target dose. Following toxicity results for combination therapy in other trials, panitumumab was withdrawn from the study. Part 2 evaluated motesanib 125 mg with chemotherapy [FOLFIRI (n = 37); FOLFOX (n = 29)]. The primary endpoint, objective response rate in patients with measurable disease by RECIST, was 20 % overall and was higher among patients receiving first-line (27 % overall; FOLFOX, 24 %; FOLFIRI, 27 %) compared with second-line therapy (14 % overall; FOLFOX, 0 %; FOLFIRI, 20 %). The most common adverse events were diarrhea, nausea, fatigue, and hypertension. We observed a low rate of cholecystitis [3 of 119 (2.5 %)], a known adverse event of motesanib and other small molecule VEGF inhibitors.Motesanib 125 mg QD in combination with FOLFIRI or FOLFOX chemotherapy was tolerated and demonstrated modest efficacy in first-/second-line mCRC.en
dc.language.isoenen
dc.titleMotesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer.en
dc.typeJournal Articleen
dc.identifier.journaltitleCancer chemotherapy and pharmacologyen
dc.identifier.affiliationDepartment of Medical Oncology, Austin Health, Heidelberg, VIC, 3084, Australia, niall.tebbutt@ludwig.edu.au.en
dc.identifier.doi10.1007/s00280-015-2694-yen
dc.description.pages993-1004en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/25772756en
dc.type.austinJournal Articleen
local.name.researcherTebbutt, Niall C
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextWith Fulltext-
item.grantfulltextopen-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
Appears in Collections:Journal articles
Files in This Item:
File SizeFormat 
25772756.pdf67.89 kBAdobe PDFView/Open
Show simple item record

Page view(s)

20
checked on Mar 28, 2024

Download(s)

64
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.